Roth Capital has revised its price target for PolyPid (PYPD, Financial), setting it at $9, a reduction from the previous $12. This adjustment is driven by an anticipated increase in PYPD's share count estimated for the first quarter of 2026. Despite this change in valuation, the firm maintains a Buy rating for the stock.
PolyPid has secured a fresh financing deal worth approximately $27 million. This influx of capital will enable the company to arrange a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) in the coming months. Additionally, the firm aims to submit the NDA for its D-PLEX100 product during the first half of 2026.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for PolyPid Ltd (PYPD, Financial) is $13.50 with a high estimate of $15.00 and a low estimate of $12.00. The average target implies an upside of 280.82% from the current price of $3.55. More detailed estimate data can be found on the PolyPid Ltd (PYPD) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, PolyPid Ltd's (PYPD, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
PYPD Key Business Developments
Release Date: May 14, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- PolyPid Ltd (PYPD, Financial) successfully concluded enrollment of the Shield 2 phase 3 trial, which is a significant milestone for the company.
- The company anticipates submitting a new drug application (NDA) for Dplex 100 in early 2026, leveraging fast track and breakthrough therapy designations.
- PolyPid Ltd (PYPD) has secured $15 million in financing, extending its cash runway into the third quarter of 2025.
- There is growing interest from potential US partners for Dplex 100, indicating strong commercial potential.
- The total addressable market for Dplex 100 in the US is substantial, with over 12 million surgeries annually, providing a significant commercial opportunity.
Negative Points
- PolyPid Ltd (PYPD) reported a net loss of $8.3 million for the first quarter of 2025, an increase from the $6.4 million loss in the same period of 2024.
- Research and development expenses increased to $6.1 million, up from $5.1 million in the previous year, driven by the Shield 2 trial.
- The company has not finalized its pricing strategy for Dplex 100, which could impact future revenue projections.
- There are uncertainties regarding the FDA inspection readiness and capacity to meet demand post-launch.
- The company's cash and cash equivalents stand at $8 million, which may not be sufficient if additional funding is not secured.
